US success offsets coronavirus impact for Gedeon Richter

3 August 2020

Hungary's largest drugmaker Gedeon Richter (RICHT: HB) has reported sales of 279 billion forint ($947 million) for the first half of 2020, up 15.4% from the same period of 2019.

The firm reported a gross profit margin for the period of 58.3%, up from 56.9%, and an operating margin of 18.8%, up from 14.2%.

While revenues held steady at 41 billion forint in Russia, formerly the firm’s largest market, USA sales grew a striking 64% to 53 billion forint, reflecting the success of Vraylar (cariprazine), an atypical antipsychotic approved in 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK